Company to Showcase Innovative Mammography Artificial Intelligence Solution at RSNA 2017
CHICAGO, Nov. 27, 2017 (GLOBE NEWSWIRE) -- RSNA 2017 -- iCAD, Inc. (NASDAQ:ICAD), a
global leader in medical technology providing innovative cancer detection and therapy solutions, today announced that customer
adoption of its PowerLook® Tomo Detection is gaining momentum. Driven by its unique ability to leverage artificial
intelligence (AI), the solution optimizes digital breast tomosynthesis (DBT) reading efficiency and improves confidence of
radiologists. This efficiency enables users to streamline workflow and supports faster, more confident detection of breast cancer.
PowerLook Tomo Detection is the first and only FDA approved concurrent-read cancer detection solution for DBT. During RSNA 2017,
Senthil Periaswamy, Ph.D., Vice President of Research at iCAD, will present on AI with breast tomosynthesis on November
28th at 1:30pm in the Machine Learning Theater located in the North Hall. The company also will showcase the complete
PowerLook Breast Health Solutions suite in booth 3142 South Hall and booth 8064 in the new Machine Learning Showcase located in the
North Hall throughout RSNA.
“Built on the latest deep learning technology, iCAD’s mammography AI solution is clinically proven to optimize radiologists’
image reading and interpretation by reducing DBT read-time by an average of 29.2 percent,” said Ken Ferry, CEO of iCAD. “Since its
FDA-approval in March, PowerLook Tomo Detection has been implemented by a number of leading breast health provider organizations
throughout the U.S.”
“PowerLook Tomo Detection is an important addition. When you’re confronted with a lot of breast tomosynthesis exams to read
daily, you can get fatigued. Now, depending on the size of the breast, I am able to cut down my reading time anywhere from 25-50%,”
Dr. Katherine Hall, Diagnostic Radiologist and Co-Director of Mammography, East Division, at Southwest Diagnostic Imaging
Center.
Recently named 2017 Product of the Year by the New Hampshire High Technology Council, PowerLook Tomo Detection utilizes a
trained algorithm developed through deep learning that automatically analyzes each tomosynthesis plane. Suspicious areas identified
are then blended into a 2D synthetic image to provide radiologists with a single, highly sensitive, enhanced image that is used to
easily navigate the tomosynthesis datasets. While PowerLook Tomo Detection is currently only available for GE Healthcare’s DBT
platforms, iCAD is developing a multi-vendor solution that is expected to be available in 2018.
In addition to PowerLook Tomo Detection, iCAD’s suite of PowerLook Breast Health Solutions includes PowerLook Mammo Detection,
which supports rapid and accurate cancer detection with 2D full-field digital mammography; and PowerLook Density Assessment, which
provides a standardized assessment of breast tissue to assist radiologists in determining the patient’s appropriate breast density
category. The solution suite provides clinicians with a wide range of tools for cancer detection and analysis that enhances
workflow and improves overall reading productivity.
For further information on iCAD’s suite of PowerLook Breast Health Solutions, visit booth 3142 in the South Hall at RSNA 2017,
or www.icadmed.com.
About iCAD, Inc.
Headquartered in Nashua, N.H., iCAD is a global leader in medical technology providing innovative cancer detection and therapy
solutions. For more information, visit www.icadmed.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks,
uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially
different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such
factors include, but are not limited to the Company’s ability to defend itself in litigation matters, to achieve business and
strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or
difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, product market acceptance,
possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in
Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the
effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the
Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,”
“anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place
undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no
obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other
risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission,
available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
Contacts:
Media Inquiries
ARPR
Erin Bocherer, (855)-300-8209
erin@arpr.com
or
Investor Relations
LifeSci Advisors
Bob Yedid, (646)-597-6989
Bob@lifesciadvisors.com
